In their evaluation of the Boehringer Advantage and Bayer Encore QA+ glucose meter systems for neonatal use, Gallagher et al. 1 say that there was no signi®cant correlation between blood glucose values and haematocrit for either meter. This is really not surprising, but it should not be taken to mean that haematocrit has no in¯uence on the results. In fact, at least two other studies have demonstrated an appreciable haematocrit in¯uence on Boehringer Advantage results, which seems to be worse at higher glucose concentrations and less of a problem at the low levels often encountered in neonates.
In their evaluation of the Boehringer Advantage and Bayer Encore QA+ glucose meter systems for neonatal use, Gallagher et al. 1 say that there was no signi®cant correlation between blood glucose values and haematocrit for either meter. This is really not surprising, but it should not be taken to mean that haematocrit has no in¯uence on the results. In fact, at least two other studies have demonstrated an appreciable haematocrit in¯uence on Boehringer Advantage results, which seems to be worse at higher glucose concentrations and less of a problem at the low levels often encountered in neonates. 2, 3 As I have no data for the Encore QA+ I cannot comment on its susceptibility to haematocrit in¯uence, but the fact that it reports results as plasma glucose does not eliminate the possibility, as it still uses a whole blood sample. Like all devices of this type, its calibration procedure will involve making assumptions about the characteristics of the sample being assayed, and when these do not apply, e.g. if haematocrit is abnormal, then anomalous results may occur.
If one ignores the observation with a glucose level greater than 8´0 mmol/L, the authors' difference plot suggests that both of the nearpatient testing methods exhibit a glucose concentration-related bias relative to the laboratory Vitros analyser, and this seems likely to have masked any correlation between glucose concentration and haematocrit that the authors attempted to detect. The only practical way to assess the in¯uence of haematocrit is by recombining different proportions of cells and plasma from a single blood specimen and then carrying out the glucose assay on the remixed samples, as is routinely done for the Medical Devices Agency evaluations. 3 Of course, I realize this would not be possible in a neonatal study, and that the authors were restricted in the avenues of investigationopen to them, but readers should not form the impression that the study shows that no haematocrit effect exists. 
Provision of interpretive comments on biochemical report forms
Marshall and Challand give a good account of the usefulness of their interpretative comments scheme; 1 however, Case 1 is misleading and indeed wrong:`46-year-old woman ± amenorrhoea for 3 months ± serum FSH 32 U/L'. I refer to the ®rst selected comment:`pregnancy . . . must be excluded as a cause of amenorrhoea'. In a clinical situation it is correct to say pregnancy is the most common cause of amenorrhoea. An FSH level of 32 U/L immediately excludes pregnancy, a condition in which FSH is totally suppressed owing to the high level of circulating oestrogens. This is fundamental, negativefeedback physiology. 2 The opinion expressed in italics is therefore inappropriate and unhelpful, and is repeated in the opinion.
Inappropriate comments for Case 1 therefore include all but comment no. 2. Comments 1 and 5 are ill-informed opinion.
There is also an error in commentary 4 ± there is no Case 4! 2 Grossman A, ed. Clinical Endocrinology, 2nd edn.
Oxford: Blackwell Science
Authors' reply
We are grateful to Dr Hazel Wilkinson for her careful attention to our paper. The points we raised in our paper are that commenting on reports is an important function of the duty biochemist, and that this function deserves both formal education and appraisal. The cases we included with the paper were chosen to illustrate some of the dif®culties associated with this function.
From one point of view, all comments on reports are`ill-informed personal opinion': those commenting never have the complete clinical picture and seldom have access to other test results (for example radiology) which may be of equal or greater importance to clinical biochemistry in making a diagnostic judgement. Those commenting are almost always working in isolation and have only their own personal experience to guide them.
With regard to the`misleading and indeed wrong' Case 1, there are inevitable (and often valid) differences of personal opinion concerning every set of results. In our opinion dogmatic comments (those boldly stating a single opinion when other possibilities exist that may be equally likely) are best avoided. The point we were making is that when`amenorrhoea' is the presenting feature, it is important that the possibility of pregnancy is mentioned. An FSH of 32 U/L in isolation cannot be said de®nitively to exclude the possibility of early pregnancy. The 3 months' amenorrhoea mentioned in the clinical information given with this case does not necessarily imply pregnancy of 3 months' duration, for which one would indeed expect a low serum FSH. It may have included a period of perimenopausal status followed by a further fertile cycle in which conception may have occurred.
We regret the typographical error in this article: for Case 4, please read Case 2. 
W J MARSHALL G S CHALLAND

Cardiac marker testing following surgery
The letter by Dr Vivekanandan highlights the use of biochemical markers of myocardial damage to detect the presence of perioperative myocardial infarction (MI) in patients undergoing surgical procedures. 1 He suggests that there is a lack of guidelines which de®ne appropriate marker(s) and their interpretation in this important group of patients. However, this is inaccurate. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Committee on Standardization of Markers of Cardiac Damage (C-SMCD) clearly supports the use of cardiac troponins (I or T) for the detection of perioperative MI in patients undergoing non-cardiac surgical procedures, instead of the use of non-cardiac speci®c markers such as total creatine kinase (CK), CK-MB, myoglobin, lactate dehydrogenase, etc.
2 For this application, the decision limit for MI diagnosis should be used. In the same document, the C-SMCD stresses the current lack of data in the scienti®c literature to make recommendations on the choice of a cardiac marker for the assessment of perioperative MI in cardiac surgery. 2 In this subgroup of patients, no biomarkers are capable of distinguishing damage due to an MI from the myocardial cell damage associated with the procedure itself. This still applies even with the recent document on rede®nition of the criteria for MI diagnosis which states that the higher the value of the cardiac marker after the procedure, the greater the damage to the myocardium, irrespective of the mechanism of injury. 
Stability of intact parathyroid hormone in blood samples
We wish to comment on the recent study of Walker and Seth, which reports that intact parathyroid hormone (iPTH) in blood collected into ethylenediaminetetraacetic acid (EDTA) tubes is more stable at room temperature than in blood collected into`plain' tubes. 1 We feel, however, that a clear distinction needs to be made between plain serum tubes and gel serum tubes (as used by Walker and Seth). We have compared the stability of iPTH in blood samples taken into gel tubes (Sarstead Monovet 4.7 mL, Z GEL) and plain glass tubes (Lip Z10/GN).
Blood was drawn from nine patients with chronic renal failure before commencement of haemodialysis. Immediately after venesection, samples were split between the plain and the gel tubes. Samples were then separated after 20 min at room temperature and serum frozen at 7208C until assayed for iPTH using the DPC Intact PTH assay on the Immulite automated immunoassay analyser.
Intact PTH values were 13% higher (P50´01, two-tailed paired t-test) in plain serum tubes [mean (SD): 7´6 (2.57) pmol/L] than in gel serum tubes [6´7 (2´19) pmol/L] (see Fig. 1 ). We suggest that these differences in iPTH values are attributable to the gel barrier or clot activator or both, especially since these results are consistent with other studies reporting a similar gel effect' on other immunoassays. 2 DPC also recommended that blood samples when collected into EDTA should ®ll the tube. Otherwise, the EDTA concentration in the sample will proportionately increase, affecting the Immulite substrate alkaline phosphatase reaction and thus lowering the iPTH result.
These factors may help explain both the variation between EDTA plasma and (gel) serum as reported 1 and the differences between this study, which reports that`serum' iPTH collected in gel tubes in unstable at 3 h, 1 and other studies which have reported that iPTH collected into plain serum tubes is stable for up to 8 h. 3, 4 In conclusion, we suggest that differences by Walker and Seth may be due to the gel separator rather than to the differences between serum and EDTA plasma. Further evaluation regarding iPTH stability in whole blood is, therefore, required. samples. We would ®rst acknowledge that our short report did not make the type of serum tube absolutely clear and we apologize for this. We used white-capped Sarstedt S Monovettes (cat no. 03.1397), which contain clotting activator coated on plastic barrier beads but no gel, as opposed to the brown-top tubes in the same range which contain in addition a gel separator. The differences we observed are not, therefore, due to the presence of gel, or to the plastic beads, as the samples were aliquoted into clean plastic tubes within 15 min of collection, but could indeed be due to the clotting activator. We can con®rm, in the light of DPC's recent recommendation, that EDTA blood tubes should be ®lled completely to avoid assay interference from high concentrations of EDTA, and that we used fully ®lled EDTA blood tubes. This recommendation from DPC, and Anderson and Gama's observations, further emphasize the need for laboratory and clinical staff to be aware of the subtle (or in some cases not so subtle) effects that blood collection systems can have on PTH results. There is clearly no substitute for checking the validity of the particular combination of blood collection system and PTH assay method used locally.
KAY WALKER JOHN SETH
Department of Clinical Biochemistry, Royal In®rmary of Edinburgh, Lauriston Place, Edinburgh EH3 9YW, UK
Effect of in¯ammatory response on trace element and vitamin status
The statements by Sattar et al. 1 on the nadirs of serum zinc and selenium and their signi®cance require clari®cation.
In support of our earlier cited references on the 6 mmol/L lower limit for zinc, we report that Halstead and Smith 2 measured plasma zinc in 324 patients in 12 groups, with a variety of disorders/conditions, and found minimum concentrations ranging from 5´8 mmol/L (liver disease) to 11´9 mmol/L (tuberculosis). Although Sattar et al. 1 correctly report that the lowest mean plasma zinc observed by Fraser et al.
3 in eight cardiac patients was 4´9+1´7 mmol/L, at least part of this low value can be explained by the haemodilution that occurs as part of the coronary bypass procedure and which complicates interpretation of changes in concentrations of metalloproteins following cardiac surgery. Their observed nadir in plasma zinc, which occurred 9 h post-operatively, was accompanied by a decrease in plasma copper from 18´3 to 13´3 mmol/L. This decrease must have involved haemodilution since caeruloplasmin (copper) is a positive acute phase reactant. The plasma copper level returned to the pre-operative value 48 h after surgery, at which time the mean plasma zinc was 6´8+1´6 mmol/L and the C-reactive protein concentration had peaked. 72 h postoperatively, the mean zinc and copper concentrations were respectively 8´2 mmol/L and 20´3 mmol/L. These observations vindicate our 6´0 mmol/L lower limit for plasma zinc. Moreover, such transient changes would be avoided by using our 3±5 day interval between monitoring trace elements. 4 Sattar et al. 1 are correct; nadirs of 0´2 mmol/L for plasma selenium have been observed in intensive care unit (ICU) patients. Hawker et al. 5 reported plasma selenium concentrations for 175 ICU patients and found that only ®ve (2´9%) had concentrations 40´3 mmol/L, and of these three (1´7%) had levels below 0´2 mmol/L. The lowest concentrations were seen in patients with surgical sepsis and with decompensated alcoholic liver disease. Forceville et al. 6 also observed plasma selenium levels as low as 0´2 mmol/L (and up to 0´72 mmol/L) in ICU patients with severe sepsis and septic shock. Thus, our limit of about 0´3 mmol/L appears at ®rst sight to be too stringent. However, 0´2 mmol/L is typical of selenium de®ciency in Keshan disease-endemic areas (<0´25 mmol/L), 7 and its ®nding in ICU patients is, to us and to others, 5,6 a cause for concern. Forceville et al. 6 gave selenium supplementation to their ICU patients with systemic immune response syndrome and observed decreases in plasma selenium in non-surviving patients and slight increases in plasma selenium in surviving patients. They concluded that a prolonged decrease in plasma selenium could explain the three-fold increase in morbidity and mortality in patients with low plasma selenium (40´7 mmol/ L) on admission, compared with other ICU patients. Although Hawker et al. 5 concluded that true selenium de®ciency was unlikely in their ICU patients, they referred speci®cally to their patients' ®rst week in ICU. They went on to say that`. . . true selenium de®ciency may develop within the ®rst few weeks of an acute illness' and`. . . in the absence of supplementation, up to half of body selenium stores could be Letters 289 lost within 4 weeks'. Monitoring trace element (selenium) concentrations every 2 to 3 months as proposed by Galloway et al. 8 would not help effective management of such patients, whereas the monitoring protocol we recommend 4 would allow early detection of the onset of any trace element de®ciency and an opportunityto rectify it.
We maintain that our statement, that in adults the lowest concentrations of serum zinc and selenium in response to disease/surgery are about 6 mmol/L and about 0´3 mmol/L, respectively, is a true re¯ection of published data. These plus our other proposed limits, together with our suggested frequency of monitoring, 1 In our opinion, it is of more importance to determine whether low circulating concentrations have any clinical signi®cance rather than attempt to delineate the lowest zinc concentrations seen in any group of ill patients. Currently, evidence on the former is lacking. Zinc concentrations do not better identify individuals with poor prognosis compared with other tests (such as C-reactive protein measurement) or other indices of disease severity. With regard to the comments of Delves and colleagues, we reiterate that there are no data to show that zinc supplementation (over and above amounts in conventional feeds) improves prognosis in hospitalized patients. Moreover, even in ICU patients to which they refer, data are lacking and therefore repeated serum zinc analyses cannot be justi®ed on clinical grounds.
With respect to selenium, Delves and colleagues quote work by Forceville et al. 2 on selenium concentrations in ICU patients. However, this was not an intervention study. The results are in fact consistent with the concept that selenium is an acute phase reactant, since lowest concentrations were found in those with a systemic in¯ammatory response. Thus, the authors' observation that lower levels of selenium were associated with increased morbidity and mortality does not prove a cause±effect relationship. It is of interest that Forceville and coworkers conclude in their paper that the ef®cacy of selenium supplementation remains to be proven.
Until such time as appropriately designed intervention trials show the clinical bene®t of additional trace element supplementation (over and above amounts in conventional feeds) in patients with low circulating concentrations, the case for frequent measurement of trace elements in ICU patients or in other patient groups cannot be recommended. In contrast, there is considerable evidence for the presence of a systemic in¯ammatory response being a major confounding factor in the interpretation of circulating concentrations of trace elements and vitamins. Fig. 1 ). In other words, a loss of signal`suppression' after repeated ®rings. This phenomenon was not encountered with a 25 ppb copper standard solution, suggesting that the interference was occurring speci®cally with aluminium (see Fig. 1 ), nor was it exhibited using a tube retained from a previous batch. The interferent could not be removed by soaking the graphite tube in nitric acid (5%) or a non-ionic detergent, Neutracon (Merck, Poole UK). However, soaking in 1% v/v Citranox (Sigma-Aldrich, Poole, UK), which contains various organic acids with ionic and non-ionic detergents, was found to virtually remove the interference. Alternatively, repeated ®rings of each new graphite tube, using the standard solution, could be carried out until a stable signal was achieved. As a remedial procedure the former is preferable, as the functional life of the graphite tube is not decreased. The use of different batches of graphite tubes from different suppliers has revealed that this problem is not speci®c to a single batch of graphite tubes (see Fig. 1 
